Imatinib Cipla

Imatinib, the active ingredient in Imatinib Cipla, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Cipla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from regulatory compliance, batch traceability, and responsive technical support throughout the supply chain.

Imatinib acts on the BCR‑ABL tyrosine kinase pathway and is indicated for several malignancies. - Chronic myeloid leukemia (CML): reduces leukemic cell proliferation, improves survival, and helps achieve cytogenetic and molecular remission. - Gastrointestinal stromal tumor (GIST): inhibits tumor growth by targeting KIT and PDGFRA mutations, leading to disease control and prolonged progression‑free survival. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to remission and disease control when combined with chemotherapy regimens.

Imatinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset that may affect appetite. - Edema: fluid retention, often noticeable in the hands, feet, or face. - Muscle cramps: painful tightening of muscles, commonly in the limbs. - Fatigue: persistent tiredness that can interfere with daily activities. - Diarrhea: loose or watery stools occurring intermittently. - Rash: skin irritation ranging from mild redness to itchy patches.

Serious or Rare Side Effects: - Neutropenia: dangerously low white blood cell count increasing infection risk. - Hepatotoxicity: elevated liver enzymes or clinically significant liver injury. - Cardiac failure: reduced heart function, especially in patients with prior cardiac disease. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis requiring urgent care. - Pulmonary hypertension: increased pressure in lung arteries leading to shortness of breath. - Bleeding complications: abnormal bruising or hemorrhage due to platelet dysfunction.

When prescribing Imatinib, clinicians should observe several safety precautions to minimize risks. - Monitor blood counts: perform regular complete blood count tests to detect neutropenia or anemia. - Assess liver function: check hepatic enzymes before initiation and periodically during therapy. - Evaluate cardiac status: review history of heart disease and monitor for signs of heart failure. - Review drug hypersensitivity: avoid use in patients with known allergy to imatinib or related compounds. - Consider pregnancy and lactation: discuss potential risks with women of childbearing potential; use only if benefits outweigh risks. - Store at room temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Imatinib can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase imatinib plasma levels, raising toxicity risk. - Strong CYP3A4 inducers (e.g., rifampin, phenytoin): can lower drug concentrations, reducing therapeutic effect. - Concurrent use with other tyrosine kinase inhibitors: may compound adverse effects and is generally avoided.

Moderate Interactions (Monitor Closely): - CYP3A4 substrate drugs (e.g., warfarin, midazolam): imatinib may affect their metabolism, requiring dose adjustments. - Diuretics (e.g., furosemide): can exacerbate fluid retention; monitor electrolytes and edema.